Review





Similar Products

94
MedChemExpress recombinant human bmp9
Dysregulation of <t>BMP9/ALK1</t> signaling and inflammation in refractory ulcerative colitis (rUC). ( A ) Heatmap depicting serum expression levels of BMP family members in healthy controls, non-rUC, and rUC patients ( n = 3 per group). Data were Z-score normalized and hierarchically clustered (red, high expression; blue, low expression). ( B ) Baseline serum levels of BMP9 and BMP10 in healthy controls ( n = 50), non-rUC patients ( n = 47), and rUC patients ( n = 48). ( C ) Spearman correlation analyses between baseline serum BMP9 levels and clinical disease activity indices, including baseline Modified Mayo Score, baseline UCEIS, post-treatment Modified Mayo Score, and post-treatment UCEIS, in patients with UC ( n = 95). ( D ) Colonic mucosal mRNA expression levels of ALK1, IL-6, TNF-α, and CCL2 in healthy controls, non-rUC, and rUC patients ( n = 4 per group). Statistical annotations for ( B , D ): (Normalized to GAPDH; Mean ± SD; Statistical significance determined by one-way ANOVA with Tukey’s post hoc test: ** p < 0.01, *** p < 0.001, ns: not significant).
Recombinant Human Bmp9, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/GDF-5%2C+Human/pmc12937769-100-10-27
Average 94 stars, based on 1 article reviews
recombinant human bmp9 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
RayBiotech inc enzyme linked immunosorbent assay elisa kit
Dysregulation of <t>BMP9/ALK1</t> signaling and inflammation in refractory ulcerative colitis (rUC). ( A ) Heatmap depicting serum expression levels of BMP family members in healthy controls, non-rUC, and rUC patients ( n = 3 per group). Data were Z-score normalized and hierarchically clustered (red, high expression; blue, low expression). ( B ) Baseline serum levels of BMP9 and BMP10 in healthy controls ( n = 50), non-rUC patients ( n = 47), and rUC patients ( n = 48). ( C ) Spearman correlation analyses between baseline serum BMP9 levels and clinical disease activity indices, including baseline Modified Mayo Score, baseline UCEIS, post-treatment Modified Mayo Score, and post-treatment UCEIS, in patients with UC ( n = 95). ( D ) Colonic mucosal mRNA expression levels of ALK1, IL-6, TNF-α, and CCL2 in healthy controls, non-rUC, and rUC patients ( n = 4 per group). Statistical annotations for ( B , D ): (Normalized to GAPDH; Mean ± SD; Statistical significance determined by one-way ANOVA with Tukey’s post hoc test: ** p < 0.01, *** p < 0.001, ns: not significant).
Enzyme Linked Immunosorbent Assay Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/Human+GDF-15+ELISA/pm42190417-64-9-14
Average 94 stars, based on 1 article reviews
enzyme linked immunosorbent assay elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems mouse recombinant 5 gdf9
Dysregulation of <t>BMP9/ALK1</t> signaling and inflammation in refractory ulcerative colitis (rUC). ( A ) Heatmap depicting serum expression levels of BMP family members in healthy controls, non-rUC, and rUC patients ( n = 3 per group). Data were Z-score normalized and hierarchically clustered (red, high expression; blue, low expression). ( B ) Baseline serum levels of BMP9 and BMP10 in healthy controls ( n = 50), non-rUC patients ( n = 47), and rUC patients ( n = 48). ( C ) Spearman correlation analyses between baseline serum BMP9 levels and clinical disease activity indices, including baseline Modified Mayo Score, baseline UCEIS, post-treatment Modified Mayo Score, and post-treatment UCEIS, in patients with UC ( n = 95). ( D ) Colonic mucosal mRNA expression levels of ALK1, IL-6, TNF-α, and CCL2 in healthy controls, non-rUC, and rUC patients ( n = 4 per group). Statistical annotations for ( B , D ): (Normalized to GAPDH; Mean ± SD; Statistical significance determined by one-way ANOVA with Tukey’s post hoc test: ** p < 0.01, *** p < 0.001, ns: not significant).
Mouse Recombinant 5 Gdf9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/Recombinant+Mouse+GDF-9+Protein/pm41688648-142-51-60
Average 94 stars, based on 1 article reviews
mouse recombinant 5 gdf9 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
RayBiotech inc goe
( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; <t>EV/GOE,</t> 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs <t>and</t> <t>GDF-9</t> –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.
Goe, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/Human+GDF-9+ELISA/pmc12693986-187-9-17
Average 93 stars, based on 1 article reviews
goe - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Novoprotein recombinant human gdf 5 bmp 14
( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; <t>EV/GOE,</t> 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs <t>and</t> <t>GDF-9</t> –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.
Recombinant Human Gdf 5 Bmp 14, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/14+5+bmp+gdf+human+recombinant/pm41160333-18-0-14
Average 86 stars, based on 1 article reviews
recombinant human gdf 5 bmp 14 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
MedChemExpress gdf 5
( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; <t>EV/GOE,</t> 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs <t>and</t> <t>GDF-9</t> –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.
Gdf 5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/GDF-5%2C+Human/pm40658817-287-18-20
Average 94 stars, based on 1 article reviews
gdf 5 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology monoclonal mouse anti gdf15 antibody g 5
( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; <t>EV/GOE,</t> 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs <t>and</t> <t>GDF-9</t> –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.
Monoclonal Mouse Anti Gdf15 Antibody G 5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/GDF-15+Antibody/pm40181460-49-15-21
Average 94 stars, based on 1 article reviews
monoclonal mouse anti gdf15 antibody g 5 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
R&D Systems g5 recombinant human long r3 igf1 r d system
( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; <t>EV/GOE,</t> 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs <t>and</t> <t>GDF-9</t> –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.
G5 Recombinant Human Long R3 Igf1 R D System, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdf+5/Recombinant+Human+GDF-5+Protein%2C+CF/pmc11853584__13395_2025_373_MOESM1_ESM-5-85-89
Average 93 stars, based on 1 article reviews
g5 recombinant human long r3 igf1 r d system - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Dysregulation of BMP9/ALK1 signaling and inflammation in refractory ulcerative colitis (rUC). ( A ) Heatmap depicting serum expression levels of BMP family members in healthy controls, non-rUC, and rUC patients ( n = 3 per group). Data were Z-score normalized and hierarchically clustered (red, high expression; blue, low expression). ( B ) Baseline serum levels of BMP9 and BMP10 in healthy controls ( n = 50), non-rUC patients ( n = 47), and rUC patients ( n = 48). ( C ) Spearman correlation analyses between baseline serum BMP9 levels and clinical disease activity indices, including baseline Modified Mayo Score, baseline UCEIS, post-treatment Modified Mayo Score, and post-treatment UCEIS, in patients with UC ( n = 95). ( D ) Colonic mucosal mRNA expression levels of ALK1, IL-6, TNF-α, and CCL2 in healthy controls, non-rUC, and rUC patients ( n = 4 per group). Statistical annotations for ( B , D ): (Normalized to GAPDH; Mean ± SD; Statistical significance determined by one-way ANOVA with Tukey’s post hoc test: ** p < 0.01, *** p < 0.001, ns: not significant).

Journal: Biomedicines

Article Title: Recombinant BMP9 Reinforces Gut Vascular Barrier in Experimental Colitis

doi: 10.3390/biomedicines14020288

Figure Lengend Snippet: Dysregulation of BMP9/ALK1 signaling and inflammation in refractory ulcerative colitis (rUC). ( A ) Heatmap depicting serum expression levels of BMP family members in healthy controls, non-rUC, and rUC patients ( n = 3 per group). Data were Z-score normalized and hierarchically clustered (red, high expression; blue, low expression). ( B ) Baseline serum levels of BMP9 and BMP10 in healthy controls ( n = 50), non-rUC patients ( n = 47), and rUC patients ( n = 48). ( C ) Spearman correlation analyses between baseline serum BMP9 levels and clinical disease activity indices, including baseline Modified Mayo Score, baseline UCEIS, post-treatment Modified Mayo Score, and post-treatment UCEIS, in patients with UC ( n = 95). ( D ) Colonic mucosal mRNA expression levels of ALK1, IL-6, TNF-α, and CCL2 in healthy controls, non-rUC, and rUC patients ( n = 4 per group). Statistical annotations for ( B , D ): (Normalized to GAPDH; Mean ± SD; Statistical significance determined by one-way ANOVA with Tukey’s post hoc test: ** p < 0.01, *** p < 0.001, ns: not significant).

Article Snippet: Immediately after seeding, HIMECs were treated with the following stimuli: recombinant human BMP9 (rhBMP9; 0–10 ng/mL), TNF-α (20 ng/mL; Novoprotein, Suzhou, China, #C008), and ML347 (150 nM; MCE, Monmouth Junction, NJ, USA, #HY-12274).

Techniques: Expressing, Activity Assay, Modification

BMP9 attenuates DSS-induced colitis in mice. ( A ) Schematic of experimental design: Acute colitis was induced in C57BL/6 mice by 3% DSS in drinking water for 7 days. The BMP9 treatment group received intraperitoneal injections of recombinant murine BMP9 (200 ng/day), while the DSS group and the control group received PBS ( n = 14 per group). ( B ) Serum BMP9(ng/mL) concentrations measured by ELISA. ( C ) Representative images of colons and quantitative analysis of colon length (cm). ( D ) Colonoscopy images (upper), H&E-stained colon sections (lower; scale bars = 100 μm), and histopathological scores. ( E ) (Upper) Dynamic body weight changes and (Lower) Disease Activity Index (DAI) scores. Data expressed as mean ± SD; * p < 0.05, two-way repeated measures ANOVA. ( F ) (Left) Relative Alk1 mRNA expression in colon tissues (RT-qPCR normalized to Gapdh). (Right) ALK1 protein concentrations (quantified by ELISA). Data presented as mean ± SD (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 ns: not significant). ( G ) Relative mRNA expression levels of IL-1β, Ccl2, Col1a1, and Col3a1 (RT-qPCR; mean ± SD). ( H ) Western blot analysis of CCL2, TGF-β, and α-SMA protein expression in colon tissues and quantitative analysis of band intensities. ( I ) Western blot detection of p-Smad1, total Smad1, and VE-cadherin proteins and quantitative analysis of band intensities.

Journal: Biomedicines

Article Title: Recombinant BMP9 Reinforces Gut Vascular Barrier in Experimental Colitis

doi: 10.3390/biomedicines14020288

Figure Lengend Snippet: BMP9 attenuates DSS-induced colitis in mice. ( A ) Schematic of experimental design: Acute colitis was induced in C57BL/6 mice by 3% DSS in drinking water for 7 days. The BMP9 treatment group received intraperitoneal injections of recombinant murine BMP9 (200 ng/day), while the DSS group and the control group received PBS ( n = 14 per group). ( B ) Serum BMP9(ng/mL) concentrations measured by ELISA. ( C ) Representative images of colons and quantitative analysis of colon length (cm). ( D ) Colonoscopy images (upper), H&E-stained colon sections (lower; scale bars = 100 μm), and histopathological scores. ( E ) (Upper) Dynamic body weight changes and (Lower) Disease Activity Index (DAI) scores. Data expressed as mean ± SD; * p < 0.05, two-way repeated measures ANOVA. ( F ) (Left) Relative Alk1 mRNA expression in colon tissues (RT-qPCR normalized to Gapdh). (Right) ALK1 protein concentrations (quantified by ELISA). Data presented as mean ± SD (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 ns: not significant). ( G ) Relative mRNA expression levels of IL-1β, Ccl2, Col1a1, and Col3a1 (RT-qPCR; mean ± SD). ( H ) Western blot analysis of CCL2, TGF-β, and α-SMA protein expression in colon tissues and quantitative analysis of band intensities. ( I ) Western blot detection of p-Smad1, total Smad1, and VE-cadherin proteins and quantitative analysis of band intensities.

Article Snippet: Immediately after seeding, HIMECs were treated with the following stimuli: recombinant human BMP9 (rhBMP9; 0–10 ng/mL), TNF-α (20 ng/mL; Novoprotein, Suzhou, China, #C008), and ML347 (150 nM; MCE, Monmouth Junction, NJ, USA, #HY-12274).

Techniques: Recombinant, Control, Enzyme-linked Immunosorbent Assay, Staining, Activity Assay, Expressing, Quantitative RT-PCR, Western Blot

BMP9 restores intestinal vascular barrier integrity in DSS-induced colitis. ( A ) Representative immunofluorescence images of VE-cadherin (red) and CD31 (green) co-localization in colon tissues (nuclei counterstained with DAPI). ( B ) Left: Schematic of FITC-dextran (4 kDa) permeability assay. Right: Quantified serum FITC fluorescence intensity 60 min post-gavage ( n = 5 per group). ( C ) Left: Schematic of Evans Blue vascular leakage assay. Right: Colonic Evans Blue extravasation quantified by absorbance at 620 nm (mean ± SD; n = 5 per group; ** p < 0.01, *** p < 0.001, ns: not significant; one-way ANOVA with Tukey’s test). ( D ) KEGG pathway analysis of RNA-seq data from colon tissues (DSS + BMP9 groups vs. DSS). ( E ) Volcano plot of differentially expressed genes. Genes highlighted in bold are key IBD-associated downregulated factors.

Journal: Biomedicines

Article Title: Recombinant BMP9 Reinforces Gut Vascular Barrier in Experimental Colitis

doi: 10.3390/biomedicines14020288

Figure Lengend Snippet: BMP9 restores intestinal vascular barrier integrity in DSS-induced colitis. ( A ) Representative immunofluorescence images of VE-cadherin (red) and CD31 (green) co-localization in colon tissues (nuclei counterstained with DAPI). ( B ) Left: Schematic of FITC-dextran (4 kDa) permeability assay. Right: Quantified serum FITC fluorescence intensity 60 min post-gavage ( n = 5 per group). ( C ) Left: Schematic of Evans Blue vascular leakage assay. Right: Colonic Evans Blue extravasation quantified by absorbance at 620 nm (mean ± SD; n = 5 per group; ** p < 0.01, *** p < 0.001, ns: not significant; one-way ANOVA with Tukey’s test). ( D ) KEGG pathway analysis of RNA-seq data from colon tissues (DSS + BMP9 groups vs. DSS). ( E ) Volcano plot of differentially expressed genes. Genes highlighted in bold are key IBD-associated downregulated factors.

Article Snippet: Immediately after seeding, HIMECs were treated with the following stimuli: recombinant human BMP9 (rhBMP9; 0–10 ng/mL), TNF-α (20 ng/mL; Novoprotein, Suzhou, China, #C008), and ML347 (150 nM; MCE, Monmouth Junction, NJ, USA, #HY-12274).

Techniques: Immunofluorescence, Permeability, Fluorescence, RNA Sequencing

BMP9/ALK1 signaling modulates neutrophil migration and endothelial tube formation. ( A ) Schematic representation of the neutrophil migration assay. ( B ) (Left) Representative fluorescence micrographs demonstrating Calcein-AM-labeled neutrophil migration through 3 μm pore Transwell inserts toward HIMECs pretreated for 2 h with: vehicle control (0 ng/mL BMP9), BMP9 (0.1, 1, or 10 ng/mL), TNF-α (20 ng/mL as positive control), or ALK1 inhibitor ML347 (150 nM). (Right) Quantitative analysis of neutrophil migration rates (mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant by two-way ANOVA with post hoc testing). ( C ) Schematic illustration of the endothelial tube formation assay protocol. ( D ) Representative phase-contrast images of tubular network formation by HIMECs cultured on growth factor-reduced Matrigel under various treatment conditions: vehicle control (0 ng/mL BMP9), BMP9 (0.1, 1, or 10 ng/mL), TNF-α (20 ng/mL), or ML347 (150 nM). ( E ) Quantitative assessment of angiogenic parameters including branch points and nodal junctions (mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001 by two-way ANOVA with appropriate post hoc comparisons).

Journal: Biomedicines

Article Title: Recombinant BMP9 Reinforces Gut Vascular Barrier in Experimental Colitis

doi: 10.3390/biomedicines14020288

Figure Lengend Snippet: BMP9/ALK1 signaling modulates neutrophil migration and endothelial tube formation. ( A ) Schematic representation of the neutrophil migration assay. ( B ) (Left) Representative fluorescence micrographs demonstrating Calcein-AM-labeled neutrophil migration through 3 μm pore Transwell inserts toward HIMECs pretreated for 2 h with: vehicle control (0 ng/mL BMP9), BMP9 (0.1, 1, or 10 ng/mL), TNF-α (20 ng/mL as positive control), or ALK1 inhibitor ML347 (150 nM). (Right) Quantitative analysis of neutrophil migration rates (mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant by two-way ANOVA with post hoc testing). ( C ) Schematic illustration of the endothelial tube formation assay protocol. ( D ) Representative phase-contrast images of tubular network formation by HIMECs cultured on growth factor-reduced Matrigel under various treatment conditions: vehicle control (0 ng/mL BMP9), BMP9 (0.1, 1, or 10 ng/mL), TNF-α (20 ng/mL), or ML347 (150 nM). ( E ) Quantitative assessment of angiogenic parameters including branch points and nodal junctions (mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001 by two-way ANOVA with appropriate post hoc comparisons).

Article Snippet: Immediately after seeding, HIMECs were treated with the following stimuli: recombinant human BMP9 (rhBMP9; 0–10 ng/mL), TNF-α (20 ng/mL; Novoprotein, Suzhou, China, #C008), and ML347 (150 nM; MCE, Monmouth Junction, NJ, USA, #HY-12274).

Techniques: Migration, Fluorescence, Labeling, Control, Positive Control, Endothelial Tube Formation Assay, Cell Culture

( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; EV/GOE, 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs and GDF-9 –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.

Journal: Science Advances

Article Title: Repair of female reproductive function by GDF-9–overexpressing extracellular vesicles via ACVR1B/SMAD2 regulation in ovarian granulosa

doi: 10.1126/sciadv.adw9006

Figure Lengend Snippet: ( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; EV/GOE, 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs and GDF-9 –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.

Article Snippet: The protein concentration of GDF-9 in control EVs and GOE was quantitatively analyzed using the ELISA kit (Raybiotech, ELH-GDF9-1).

Techniques: In Vitro, Concentration Assay, Flow Cytometry